Bristol-Myers Squibb Co. and Taris BioMedical LLC will collaborate to evaluate Taris' TAR-200, in combination with Bristol-Myers' Opdivo, in patients with bladder cancer.

Under the collaboration, the combination will be evaluated in a phase 1b trial in patients with muscle invasive bladder cancer who are scheduled for radical cystectomy, or the removal of the entire bladder.

Bristol-Myers also made an equity investment in TARIS as part of the collaboration.